These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 213081)

  • 1. Sitosterol in juvenile type II hyperlipoproteinemia.
    Schlierf G; Oster P; Heuck CC; Raetzer H; Schellenberg B
    Atherosclerosis; 1978 Aug; 30(4):245-8. PubMed ID: 213081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Sitosterol in familial hyperlipoproteinemia type II. A randomized double-blind cross-over study].
    Oster P; Schlierf G; Heuck CC; Greten H; Gundert-Remy U; Haase W; Klose G; Nothelfer A; Raetzer H; Schellenberg B; Schmidt-Gayk H
    Dtsch Med Wochenschr; 1976 Sep; 101(36):1308-11. PubMed ID: 182445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Beta-sitosterin in unsuccessfully pretreated patients with hypercholesteremia. Simultaneously, a contribution to dose dependence].
    Mühlfellner G; Mühlfellner O; Kaffarnik H
    Med Klin; 1976 Apr; 71(18):775-8. PubMed ID: 178987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ileal exclusion on lipoprotein sitosterol in familial hypercholesterolaemia.
    Koivisto PV; Miettinen TA
    Scand J Clin Lab Invest; 1988 Apr; 48(2):193-8. PubMed ID: 3358098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum lipoproteins and lecithin: cholesterol acyltransferase (LCAT) activity in hypercholesterolemic subjects given beta-sitosterol.
    Weisweiler P; Heinemann V; Schwandt P
    Int J Clin Pharmacol Ther Toxicol; 1984 Apr; 22(4):204-6. PubMed ID: 6715090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Familial hyperlipoproteinemia type III].
    Patsch JR; Patsch W; Sailer S; Braunsteiner H
    Dtsch Med Wochenschr; 1976 Oct; 101(44):1612-9. PubMed ID: 185039
    [No Abstract]   [Full Text] [Related]  

  • 7. Type III hyperlipoproteinemia: rise in high-density lipoprotein levels in response to therapy.
    Falko JM; Witztum JL; Schonfeld G; Weidman SW; Kolar JB
    Am J Med; 1979 Feb; 66(2):303-10. PubMed ID: 218451
    [No Abstract]   [Full Text] [Related]  

  • 8. [Beta-sitosterin in the treatment of essential type II hyperlipoproteinemias].
    Kaffarnik H; Mühlfellner G; Mühlfellner O; Schneider J; Hausmann L; Zöfel P; Schubotz R; Fuchs F
    Fortschr Med; 1977 Dec; 95(46):2785-7. PubMed ID: 590905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment of severe familial hypercholesterolemia in children: effect of sitosterol and bezafibrate.
    Becker M; Staab D; Von Bergman K
    Pediatrics; 1992 Jan; 89(1):138-42. PubMed ID: 1727999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison between combination therapy with clofibrate and beta-pyridylcarbinol and clofibrate monotherapy (author's transl].
    Mordasini R; Müller A; Klose G; Middelhoff G; Augustin J; Haase W; Greten H
    MMW Munch Med Wochenschr; 1978 Apr; 120(15):525-8. PubMed ID: 206826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of clofibrate, nicotinic acid and diet on the properties of the plasma lipoproteins in a subject with type III hyperlipoproteinemia.
    Patsch JR; Yeshurun D; Jackson RL; Gotto AM
    Am J Med; 1977 Dec; 63(6):1001-9. PubMed ID: 204188
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of severe familial hypercholesterolemia in childhood with sitosterol and sitostanol.
    Becker M; Staab D; Von Bergmann K
    J Pediatr; 1993 Feb; 122(2):292-6. PubMed ID: 8429449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative treatment of hyperlipoproteinaemias in chimpanzees.
    Vastesaeger M; Blaton V; Declercq B; Vercruysse J; Vandamme D; Peeters H; Mortelmans J
    Acta Zool Pathol Antverp; 1974; 58(0):79-96. PubMed ID: 4365833
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of hyperlipidemia.
    Levy RI; Morganroth J; Rifkind BM
    N Engl J Med; 1974 Jun; 290(23):1295-301. PubMed ID: 4363888
    [No Abstract]   [Full Text] [Related]  

  • 15. Colestipol in familial type II hyperlipoproteinemia: a three-year trial.
    Harvengt C; Desager JP
    Clin Pharmacol Ther; 1976 Sep; 20(3):310-4. PubMed ID: 182429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary and drug treatment of primary hyperlipoproteinemia.
    Ann Intern Med; 1972 Aug; 77(2):267-94. PubMed ID: 4345081
    [No Abstract]   [Full Text] [Related]  

  • 17. Achilles tendinitis and tenosynovitis. A diagnostic manifestation of familial type II hyperlipoproteinemia in children.
    Shapiro JR; Fallat RW; Tsang RC; Glueck CJ
    Am J Dis Child; 1974 Oct; 128(4):486-90. PubMed ID: 4369742
    [No Abstract]   [Full Text] [Related]  

  • 18. Pediatric familial type II hyperlipoproteinemia: therapy with diet and colestipol resin.
    Glueck CJ; Fallat RW; Mellies M; Tsang RC
    Pediatrics; 1976 Jan; 57(1):68-74. PubMed ID: 174057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial hyperlipidemias. Diagnosis and treatment.
    Fleischmajer R; Dowlati Y; Reeves JR
    Arch Dermatol; 1974 Jul; 110(1):43-50. PubMed ID: 4371196
    [No Abstract]   [Full Text] [Related]  

  • 20. Familial aggregation of lipids and lipoproteins and early identification of dyslipoproteinemia. The Collaborative Lipid Research Clinics Family Study.
    Morrison JA; Namboodiri K; Green P; Martin J; Glueck CJ
    JAMA; 1983 Oct; 250(14):1860-8. PubMed ID: 6620483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.